Pharmaceuticals, Biotechnology and Life Sciences
DBV Technologies has finished the patient enrollment in the Phase III study testing the use of Viaskin Peanut, for the treatment of peanut allergic children four to 11 years of age, including patients with a history of severe anaphylaxis.
TiGenix’s study of Cx601 showed that results after two years are consistent with the results communicated at week 24 and week 52, said Dr Marie Paule Richard, Chief Medical Officer of TiGenix.
IntegraGen SA, a company specializing in the decoding of the human genome and performing interpretable genomic tests for academic and private laboratories and a developer of diagnostic tools in oncology, and Laboratoire CERBA, has signed a licensing agreement allowing Laboratoire CERBA to develop and provide to prescribing clinicians a test based on IntegraGen’s proprietary miR-31-3p biomarker.
Esperite N.V. has announced a €1 million private placement of 100 convertible notes with a principal amount of €10,000 each, with share subscription warrants attached (the “First Tranche Notes and Warrants”).
OptiBiotix health has signed a manufacturing, supply, and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.
Valisek, a joint venture between ValiRx, a clinical stage biotechnology company and Tangent Reprofiling Limited, plans to add a third clinical site, in Tbilisi, Georgia.
Innate Pharma has reported its consolidated financial results for the year ended December 31, 2016.
Swedish Orphan Biovitrum AB known as Sobi said Tuesday that the FDA has approved increased shelf life and extended out-of-refrigeration for Orfadin capsules.
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.
Herantis Pharma clinical study with the company’s innovative gene therapy investigational product Lymfactin for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety.